17
Mar

About two months ago, Nektar was talking up a big expansion, making way for the new staffers that would be needed to start commercializing the breast cancer drug NKTR-102. Today, the biotech may be rethinking that plan, as the drug failed in a pivotal late-stage study.

…read more

Source: Nektar looks for the positive in a failed PhIII breast cancer study

    

0 No comments